Please wait while the formulary information is being retrieved.
HEPLISAV-B (hepatitis B vaccine recombinant/vaccine adjuvant CpG 1018/PF)
- Hepatitis B prevention
(PF) 20 mcg/0.5 mL intramuscular syringe
- Inject 0.5 milliliter (20 mcg) by intramuscular route once
Hepatitis B prevention
- Inject 0.5 milliliter (20 mcg) by intramuscular route once
- None
Contraindicated
- fingolimod
- Gilenya
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- Fever
- Multiple sclerosis
HEPLISAV-B (hepatitis B vaccine recombinant/vaccine adjuvant CpG 1018/PF)
- Hepatitis B prevention
- None
- Fatigue
- Injection site sequelae
More Frequent
Severe
Less Severe
- None
- Dizziness
- Erythema
- Fever
- Headache disorder
- Induration of skin
- Pain
- Vertigo
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Anaphylaxis
- Angioedema
- Apnea
- Bell's palsy
- Bronchospastic pulmonary disease
- Encephalitis
- Encephalopathy
- Erythema multiforme
- Erythema nodosum
- Guillain-barre syndrome
- Herpes zoster
- Lichen planus
- Meningitis
- Muscle weakness
- Myelitis
- Optic neuritis
- Purpura
- Seizure disorder
- Serum sickness
- Stevens-johnson syndrome
- Syncope
- Thrombocytopenic disorder
- Vasculitis
Less Severe
- Abdominal pain with cramps
- Agitation
- Alopecia
- Anorexia
- Arthralgias
- Arthritis
- Back pain
- Chills
- Conjunctivitis
- Constipation
- Diarrhea
- Drowsy
- Dyspepsia
- Earache
- Ecchymosis
- Eczema
- Flu-like symptoms
- Flushing
- General weakness
- Hyperhidrosis
- Hypesthesia
- Hypotension
- Insomnia
- Irritability
- Keratitis
- Lymphadenopathy
- Malaise
- Migraine
- Myalgias
- Nausea
- Neck pain
- Neck stiffness
- Palpitations
- Paresthesia
- Peripheral sensory neuropathy
- Petechiae
- Pruritus of skin
- Shoulder pain
- Skin rash
- Tachycardia
- Tinnitus
- Upper respiratory infection
- Urticaria
- Visual changes
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Hepatitis B Vaccine_Adjuvanted
No safety and efficacy established for adjuvanted vaccine.
- 1 Day – 18 Years
- No safety and efficacy established for adjuvanted vaccine.
Hepatitis B Virus Vaccine
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects.
Sodium Phosphate,dibasic
- Severity Level:
2
- Additional Notes: Insufficient data available.
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Hepatitis B Virus Vaccine
Insufficient data available
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Hepatitis B prevention | |
Z23 | Encounter for immunization |
0-9 | A-Z |
---|---|
Z23 | Encounter for immunization |
Formulary Reference Tool